-
Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China
•
Dizal Pharmaceutical Co., Ltd (SHA: 688192) and Burning Rock Ltd (NASDAQ: BNR, FRA: 6BU0) have announced a significant regulatory milestone in China’s precision medicine space. Their jointly developed companion diagnostic (CDx) for epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), designed to pair with the targeted therapy sunvozertinib,…
-
Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China
•
Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in the field of tumor companion diagnostics (CDx), this time with the German multinational corporation, Bayer. Previously Burning Rock had collaborated with Germany-based Merck KGaA in late 2021 for the development of CDx to support Merck’s…
-
Burning Rock’s CanCatch MRD Product Shows Superiority in Postoperative NSCLC Monitoring
•
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has revealed positive findings from a five-year clinical trial of its liquid assay-based personalized minimal residual disease (MRD) product, CanCatch (PROPHET panel; Patient-specific pROgnostic and Potential tHErapeutic marker Tracking). The results, published in Cancer Cell under the title “Individualized tumor-informed circulating tumor…
